Recent Updates
Recently added Catalysts

Epilepsy: one US-listed biotech with a clinical-stage programme

Neurology & PsychiatryUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.6Buniverse median $1.20B
Allocated capital$639M$2.6B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank187/299crowding rank 197

Epilepsy is uncontested. Supernus Pharmaceuticals (SUPN) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with SPN-817 in phase 2.

There is no public comparable to price it against. SUPN spreads its $2.6B market cap across 4 indications, so $639M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$639M of allocated capital sits in Epilepsy, ranking it 187th of 299 indications by the money committed to it.

Companies developing drugs for Epilepsy 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
SUPNSupernus PharmaceuticalsSPN-817Phase 21$2.6BNo4No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Epilepsy counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Epilepsy has one competitor and a median of $2.6B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Frontotemporal Dementia1 company · $729M · median $3.6BUncontestedAcute Ischemic Stroke2 companies · $486M · median $1.3BConcentrated betMajor Depressive Episode1 company · $426M · median $1.3BUncontestedNeurogenic Orthostatic Hypotension1 company · $887M · median $887MUncontestedPrimary Erythromelalgia1 company · $342M · median $2.4BUncontestedCervical Spinal Cord Injury1 company · $278M · median $278MUncontestedOsteoarthritis Knee Pain1 company · $265M · median $1.1BUncontestedAcute Postoperative Pain1 company · $265M · median $1.1BUncontested

Epilepsy pipeline questions

Which biotech companies are developing drugs for Epilepsy?

Supernus Pharmaceuticals (SUPN, SPN-817, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Epilepsy.

How advanced is the Epilepsy pipeline?

Of the 1 clinical-stage programme in Epilepsy, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Epilepsy?

No. SUPN is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Epilepsy, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map